Any feedback?
Literature summary for 2.7.7.49 extracted from
- Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C (2010), Retrovirology, 7, 80.
Application
| Application | Comment | Organism |
|---|---|---|
| drug development | HIV-1 reverse transcriptase is a major target of antiviral therapy | Human immunodeficiency virus 1 |
| medicine | HIV-1 reverse transcriptase is a major target of antiviral therapy | Human immunodeficiency virus 1 |
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| recombinant expression of His-tagged subtype B HIV-1 reverse transcriptase in Escherichia coli strain M15 | Human immunodeficiency virus 1 |
| recombinant expression of His-tagged subtype C HIV-1 reverse transcriptase in Escherichia coli strain M15 | Human immunodeficiency virus 1 |
Protein Variants
| Protein Variants | Comment | Organism |
|---|---|---|
| M184V | the fidelity of DNA polymerization of the mutant HIV-1 RT is significantly higher than that of wild-type enzyme | Human immunodeficiency virus 1 |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one | - |
Human immunodeficiency virus 1 |  |
| Etravirine | - |
Human immunodeficiency virus 1 | |
| lamivudine | - |
Human immunodeficiency virus 1 | |
| additional information | comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview | Human immunodeficiency virus 1 | |
| nevirapine | - |
Human immunodeficiency virus 1 | |
| Tenofovir | - |
Human immunodeficiency virus 1 | |
| tenofovir diphosphate | - |
Human immunodeficiency virus 1 | |
| zidovudine | - |
Human immunodeficiency virus 1 | |
Metals/Ions
| Metals/Ions | Comment | Organism | Structure |
|---|---|---|---|
| Mg2+ | required | Human immunodeficiency virus 1 | |
Molecular Weight [Da]
| Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
|---|---|---|---|
| 51000 | - |
1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
| 66000 | - |
1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 | - |
diphosphate + DNAn+1 | - |
? | |
| deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 M01 | - |
diphosphate + DNAn+1 | - |
? | |
| deoxynucleoside triphosphate + DNAn | Human immunodeficiency virus 1 BG05 | - |
diphosphate + DNAn+1 | - |
? | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Human immunodeficiency virus 1 | AF324493 | subtype B | - |
| Human immunodeficiency virus 1 | Q8Q2U5 | subtype C | - |
| Human immunodeficiency virus 1 | Q8Q2V9 | subtype C | - |
| Human immunodeficiency virus 1 BG05 | Q8Q2U5 | subtype C | - |
| Human immunodeficiency virus 1 M01 | Q8Q2V9 | subtype C | - |
Posttranslational Modification
| Posttranslational Modification | Comment | Organism |
|---|---|---|
| proteolytic modification | p66/p51 heterodimer formation through protease cleavage | Human immunodeficiency virus 1 |
Purification (Commentary)
| Purification (Comment) | Organism |
|---|---|
| recombinant His-tagged subtype B HIV-1 reverse transcriptase in heterodimeric form from Escherichia coli strain M15 by metal affinity chromatography and ion exchange chromatography to homogeneity | Human immunodeficiency virus 1 |
| recombinant His-tagged subtype C HIV-1 reverse transcriptase in heterodimeric form from Escherichia coli strain M15 by metal affinity chromatography and ion exchange chromatography to homogeneity | Human immunodeficiency virus 1 |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 | diphosphate + DNAn+1 | - |
? | |
| deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 M01 | diphosphate + DNAn+1 | - |
? | |
| deoxynucleoside triphosphate + DNAn | - |
Human immunodeficiency virus 1 BG05 | diphosphate + DNAn+1 | - |
? | |
| dTTP + DNAn | - |
Human immunodeficiency virus 1 | diphosphate + DNAn+1 | - |
? | |
| dTTP + DNAn | - |
Human immunodeficiency virus 1 M01 | diphosphate + DNAn+1 | - |
? | |
| dTTP + DNAn | - |
Human immunodeficiency virus 1 BG05 | diphosphate + DNAn+1 | - |
? | |
| additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
| additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview.. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
| additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-)ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 | ? | - |
? | |
| additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview.. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 M01 | ? | - |
? | |
| additional information | recombinant subtype B and C HIV-1 reverse transcriptases show similar enzyme activities and efficiency of tRNA-primed (-) ssDNA synthesis, processivity, fidelity and RNase H activity, as well as susceptibilities to drugs, overview. The enzyme also exhibits RNase H activity, EC 3.1.13.2 | Human immunodeficiency virus 1 BG05 | ? | - |
? | |
Subunits
| Subunits | Comment | Organism |
|---|---|---|
| dimer | 1 * 66000 + 1 * 51000, SDS-PAGE | Human immunodeficiency virus 1 |
| More | p66/p51 heterodimer formation through protease cleavage. Although p51 provides RT with essential structural and conformational stability, p66 is the catalytically active subunit and includes the N-terminal polymerase domain (residues 1-321) and C-terminal RNase H domain (residues 441-560), linked by a connection domain | Human immunodeficiency virus 1 |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| HIV-1 reverse transcriptase | - |
Human immunodeficiency virus 1 |
| HIV-1 RT | - |
Human immunodeficiency virus 1 |
Temperature Optimum [°C]
| Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|
| 37 | - |
assay at | Human immunodeficiency virus 1 |
pH Optimum
| pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|
| 7.8 | - |
assay at | Human immunodeficiency virus 1 |
General Information
| General Information | Comment | Organism |
|---|---|---|
| additional information | although p51 provides RT with essential structural and conformational stability, p66 is the catalytically active subunit and includes the N-terminal polymerase domain (residues 1-321) and C-terminal RNase H domain (residues 441-560), linked by a connection domain | Human immunodeficiency virus 1 |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
